Skip to main content

. 1978 Dec 16;2(6153):1684. doi: 10.1136/bmj.2.6153.1684

Response to penicillamine of lead concentrations in CSF and blood in patients with motor neurone disease.

A O House, R J Abbott, D L Davidson, I T Ferguson, J A Lenman

PMCID: PMC1608994 PMID: 737439

1684

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Campbell A. M., Williams E. R., Barltrop D. Motor neurone disease and exposure to lead. J Neurol Neurosurg Psychiatry. 1970 Dec;33(6):877–885. doi: 10.1136/jnnp.33.6.877. [DOI] [PMC free article] [PubMed] [Google Scholar]
Conradi S., Ronnevi L. O., Vesterberg O. Abnormal tissue distribution of lead in amyotrophic lateral sclerosis. J Neurol Sci. 1976 Oct;29(2-4):259–265. doi: 10.1016/0022-510x(76)90175-1. [DOI] [PubMed] [Google Scholar]
Conradi S., Ronnevi L. O., Vesterberg O. Increased plasma levels of lead in patients with amyotrophic lateral sclerosis compared with control subjects as determined by flameless atomic absorption spectrophotometry. J Neurol Neurosurg Psychiatry. 1978 May;41(5):389–393. doi: 10.1136/jnnp.41.5.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
Currier R. D., Haerer A. F. Amyotrophic lateral sclerosis and metallic toxins. Arch Environ Health. 1968 Nov;17(5):712–719. doi: 10.1080/00039896.1968.10665310. [DOI] [PubMed] [Google Scholar]
Jusić A., Sostarko M. Improvement of spinal amyotrophy by penicillamine therapy. Lancet. 1977 Nov 12;2(8046):1034–1035. [PubMed] [Google Scholar]

ACTIONS

RESOURCES